Viramontes B E, Camilleri M, McKinzie S, Pardi D S, Burton D, Thomforde G M
Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Am J Gastroenterol. 2001 Sep;96(9):2671-6. doi: 10.1111/j.1572-0241.2001.04138.x.
To evaluate the influence of gender on the effect of a 5-HT3 antagonist, alosetron, 1 mg b.i.d., on GI and colonic transit in D-IBS.
Thirty patients (15 male, 15 female) with D-IBS received 1 mg b.i.d. alosetron for 6 wk. Transit was measured by scintigraphy at baseline and at the end of treatment.
Alosetron, 1 mg b.i.d., significantly retarded small bowel and, proximal and overall colonic transit in the 30 patients with D-IBS. The effect of alosetron on the primary endpoint, colonic geometric center at 24 h, was significantly greater in females than in males (p < 0.05). However, two females showed no slowing of colonic transit on treatment. Among male patients, two of 15 had a slowing of colonic transit at 24 h that was greater than the mean change in female patients, suggesting responsiveness to alosetron among a subgroup of males.
A 5-HT3 antagonist, alosetron, significantly retards small intestinal and colonic transit in diarrhea-predominant IBS patients, with significantly greater female to male responsiveness. Gender partly contributes to differences in the serotonergic control of intestinal and colonic transit in patients with D-IBS.
评估性别对5-羟色胺3（5-HT3）拮抗剂阿洛司琼（每日两次，每次1毫克）治疗腹泻型肠易激综合征（D-IBS）时对胃肠道及结肠转运作用的影响。
30例D-IBS患者（男15例，女15例）接受每日两次、每次1毫克阿洛司琼治疗，为期6周。在基线期和治疗结束时通过闪烁扫描法测量转运情况。
每日两次、每次1毫克的阿洛司琼显著延缓了30例D-IBS患者的小肠、近端结肠及整个结肠的转运。阿洛司琼对主要终点指标（24小时结肠几何中心）的作用在女性中显著大于男性（p < 0.05）。然而，有两名女性在治疗时结肠转运未出现减慢。在男性患者中，15例中有两例在24小时时结肠转运减慢程度大于女性患者的平均变化，提示部分男性亚组对阿洛司琼有反应。
5-HT3拮抗剂阿洛司琼显著延缓腹泻型肠易激综合征患者的小肠和结肠转运，女性对其反应明显大于男性。性别在一定程度上导致了D-IBS患者肠道和结肠转运的5-羟色胺能控制差异。
